Overview

Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
To investigate the pharmacokinetics (PK) of POL7080 in subjects with renal function impairment after single intravenous (IV) infusion of POL7080
Phase:
Phase 1
Details
Lead Sponsor:
Polyphor Ltd.
Treatments:
Murepavadin